

Preliminary Amendment filed January 8, 2007

RECEIVED  
CENTRAL FAX CENTER  
JAN 08 2007

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 15-16 are canceled without prejudice or disclaimer.

Claims 1-14 are amended.

**Listing of Claims:**

1. (Currently Amended) ~~A pharmaceutical composition comprising metformin, a statin, and one or more pharmaceutically acceptable excipients.~~ Method for controlling or decreasing glycaemia in non insulin dependent diabetes subjects comprising the co-administration of a therapeutically effective dose of metformin and a statin as active components.
2. (Currently Amended) ~~A pharmaceutical composition~~ The method according to claim 1, wherein the statin is selected from the group consisting of lovastatin, fluvastatin, atorvastatin, simvastatin, pravastatin, itavastatin and rosuvastatin.
3. (Currently Amended) ~~A pharmaceutical composition~~ The method according to claim 1 or 2, wherein metformin is in the form of a salt selected from the group consisting of the hydrochloride, acetate, benzoate, citrate, fumarate, embonate, chlorophenoxyacetate, glycolate, palmoate, aspartate, methanesulphonate, maleate, parachlorophenoxyisobutyrate, formate, lactate, succinate, sulphate, tartrate, cyclohexanecarboxylate, hexanoate, octanoate, decanoate, hexadecanoate, octadecanoate, benzenesulphonate, trimethoxybenzoate, paratoluenesulphonate, adamantanecarboxylate, glycoxylate, glutamate, pyrrolidonecarboxylate, naphthalenesulphonate, 1-glucosephosphate, nitrate, sulphite, dithionate and phosphate.
4. (Currently Amended) ~~A pharmaceutical composition~~ The method according to ~~any of claims~~ claim 1 to 3, wherein metformin is in the form of a salt selected from the group consisting of the hydrochloride, fumarate, embonate, and chlorophenoxyacetate.

Preliminary Amendment filed January 8, 2007

5. (Currently Amended) ~~A pharmaceutical composition~~The method according to ~~any of claims~~claim 1 to 4, wherein the statin is in the form of a salt selected from the group consisting of the sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
6. (Currently Amended) ~~A pharmaceutical composition~~The method according to ~~any of claims~~claim 1 to 5, wherein ~~said composition~~a unit dose administered contains from 0.1 to 100 mg of a statin.
7. (Currently Amended) ~~A pharmaceutical composition~~The method according to ~~any of claims~~claim 1 to 6, wherein ~~said composition~~a unit dose administered contains from 200 to 2000 mg of metformin.
8. (Currently Amended) ~~A pharmaceutical composition~~The method according to ~~any of claims~~claim 1 to 7, wherein the weight ratio of statin to metformin administered is in the range of about 1:2 to about 1:20000.
9. (Currently Amended) ~~A pharmaceutical composition~~The method according to ~~any of claims~~claim 1 to 8, wherein ~~said composition is in the~~the active components are administered in at least one form selected from the group consisting of: powders, tablets, coated tablets, dragees, troches, lozenges, dispersible granules, capsules or and sachets.
10. (Currently Amended) ~~A pharmaceutical composition according to any of claims 1 to 8, wherein said composition is in the form of a solution, a suspension or an emulsion~~The method according to claim 1, wherein the active components are administered in at least one form selected from the group consisting of: solutions, suspensions and emulsions.
11. (Currently Amended) ~~A pharmaceutical composition~~The method according to ~~any of claims~~claim 1 to 10, wherein ~~the pharmaceutical composition is~~at least one active component is administered in the form of a controlled-release composition.

Preliminary Amendment filed January 8, 2007

12. (Currently Amended) ~~A composition comprising metformin and a statin for use as an active therapeutic product~~The method according to claim 1, wherein at least one active component is administered orally.
13. (Currently Amended) ~~Use of metformin and a statin in the manufacture of a pharmaceutical composition for the prevention, inhibition or treatment of hyperglycaemia, non insulin dependent diabetes, dyslipidaemia, hyperlipidemia, hypercholesterolemia, obesity or cardiovascular diseases~~The method according to claim 1, wherein the metformin and the statin are co-administered in the form of a combination composition wherein each dosage unit has a fixed ratio of the two active components.
14. (Currently Amended) ~~Use~~The method according to claim 13, wherein the pharmaceutical composition is metformin and the statin are co-administered orally in separate dosage units from a kit comprising separate dosage units of metformin and of a statin.

15-16 (canceled)